VU534 is a NAPE-PLD activator, with an EC 50 of 0.30 μM. VU534 is dual inhibitors of FAAH and sEH ( IC 50 of 1.2 μM). VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study [1] .
Products | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Infection | Products > Disease Areas > Pain | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > FAAH | Products > Signaling Pathways > Epoxide Hydrolase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.